3E8.scFv.Cys-IR800 TAG-72 Imaging for Real-Time Tumor Resection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging technologies for colorectal cancer surgery are inadequate for real-time intraoperative use, as they lack cancer specificity and are too slow, missing occult disease sites and requiring extensive manual measurements, which complicates complete tumor resection.
Innovation Solution
Development of anti-TAG-72 imaging agents, such as 3E8.scFv.Cys-IR800, that utilize a site-specific NIRF dye conjugated to a cysteine residue on a 28 kDa antibody fragment, allowing real-time optical surgical navigation with high specificity and rapid renal excretion, reducing background liver signal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radioguided antigen-directed surgery (RADS) is used, then cancer-specific detection is improved, but measurement speed and operational efficiency deteriorate due to manual measurements requiring 1 minute for each 2-3 cm
Solution Approach 1:
The patent replaces manual mechanical measurement with optical imaging technology. The NIRF imaging agent provides visual information that can be captured and processed by optical detection systems, eliminating the need for manual probe measurements and enabling real-time visualization of tumor boundaries during surgery.
Solution Approach 2:
The patent utilizes near-infrared fluorescence imaging to visualize tumor boundaries. The NIRF imaging agent emits fluorescent light that can be detected by optical imagers, providing real-time color/fluorescence information about tumor locations and boundaries, replacing manual detection methods.
2Loss of information
If conventional external imaging (MRI, US, CT) is used, then preoperative planning is improved, but real-time intraoperative capability is lost due to long acquisition times of 15 minutes to one hour per image
Solution Approach 1:
The patent administers the NIRF imaging agent before surgery to allow accumulation and localization at tumor sites. This preliminary action enables real-time visualization during surgery without requiring lengthy preoperative imaging, as the agent is already in place and emitting detectable signals when needed.
Solution Approach 2:
The patent substitutes conventional slow acquisition imaging modalities with optical imaging technology. The optical imager can capture real-time fluorescence signals instantly, replacing the 15-minute to one-hour acquisition times of CT, MRI, and US, enabling dynamic intraoperative decision-making.
3Reliability
If full-length antibodies are used for imaging, then target binding affinity is improved, but renal excretion and background signal reduction deteriorate
Solution Approach 1:
The patent uses antibody fragments (scFv) instead of full-length antibodies. This segmentation reduces the molecular size, enabling faster renal excretion and reduced background signal in organs like the liver, while maintaining sufficient target binding affinity through the preserved variable regions responsible for antigen recognition.
Solution Approach 2:
The patent changes the molecular size parameter of the binding agent by using antibody fragments rather than full-length antibodies. This parameter change improves renal clearance kinetics and reduces non-specific binding background, while the affinity is maintained through optimization of the fragment's variable regions.
4Ease of operation
If visual inspection and palpation are used during surgery, then surgical simplicity is maintained, but detection of occult disease sites deteriorates
Solution Approach 1:
The patent introduces optical fluorescence imaging that provides real-time color/fluorescence information about tumor boundaries and occult disease sites. This visual information complemented by the surgeon's existing visual inspection and palpation skills, enhancing detection accuracy without significantly complicating the surgical procedure.
Solution Approach 2:
The patent introduces optical imaging as an intermediary technology that bridges the gap between simple visual inspection and complex molecular imaging. The NIRF imaging agent acts as a mediator that translates molecular tumor presence into visible optical signals, enhancing detection without requiring complex surgical interventions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables real-time visualization of colorectal tumors during surgery, enhancing surgical precision by accurately identifying and removing cancerous tissues over a wide field of view, while minimizing liver background interference.
Implementation Method 1
the first detectable label comprises any dicyanine dye (such as, for example IRdye800, AlexaFluor 790, ZW-800 (Frangioni et al), Indocyanine Green, and SO456) that emits fluorescent light that is detectable on a clinical optical NIRF imager at primarily above 800 nm
Data Source
AI summary
Disclosed are compositions are anti-TAG-72 imaging agents and methods of their usc.